MedPath

Ravicti

These highlights do not include all the information needed to use RAVICTI safely and effectively. See full prescribing information for RAVICTI. RAVICTI (glycerol phenylbutyrate) oral liquid Initial U.S. Approval: 1996

Approved
Approval ID

900e7dc0-9afe-4f50-80de-90567bb78519

Product Type

HUMAN PRESCRIPTION DRUG LABEL

Effective Date

Sep 13, 2021

Manufacturers
FDA

Horizon Therapeutics USA, Inc.

DUNS: 033470838

Products 1

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

glycerol phenylbutyrate

Product Details

FDA regulatory identification and product classification information

FDA Identifiers
NDC Product Code75987-050
Application NumberNDA203284
Product Classification
M
Marketing Category
C73594
G
Generic Name
glycerol phenylbutyrate
Product Specifications
Route of AdministrationORAL
Effective DateSeptember 13, 2021
FDA Product Classification

INGREDIENTS (1)

GLYCEROL PHENYLBUTYRATEActive
Quantity: 1.1 g in 1 mL
Code: ZH6F1VCV7B
Classification: ACTIB

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

Ravicti - FDA Drug Approval Details